Format

Send to

Choose Destination
J Med Chem. 2015 Feb 26;58(4):1846-61. doi: 10.1021/jm501680m. Epub 2015 Feb 4.

Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.

Author information

1
Medicinal Chemistry, ‡Discovery Biology, §Crystallography/Modeling Facility, Translational Research Institute, ∥Department of Molecular Therapeutics, and ⊥Department of Cancer Biology, The Scripps Research Institute, Scripps Florida , 130 Scripps Way, No. 2A1, Jupiter, Florida 33458, United States.

Abstract

The discovery/optimization of bis-aryl ureas as Limk inhibitors to obtain high potency and selectivity and appropriate pharmacokinetic properties through systematic SAR studies is reported. Docking studies supported the observed SAR. Optimized Limk inhibitors had high biochemical potency (IC50 < 25 nM), excellent selectivity against ROCK and JNK kinases (>400-fold), potent inhibition of cofilin phosphorylation in A7r5, PC-3, and CEM-SS T cells (IC50 < 1 μM), and good in vitro and in vivo pharmacokinetic properties. In the profiling against a panel of 61 kinases, compound 18b at 1 μM inhibited only Limk1 and STK16 with ≥80% inhibition. Compounds 18b and 18f were highly efficient in inhibiting cell-invasion/migration in PC-3 cells. In addition, compound 18w was demonstrated to be effective on reducing intraocular pressure (IOP) on rat eyes. Taken together, these data demonstrated that we had developed a novel class of bis-aryl urea derived potent and selective Limk inhibitors.

PMID:
25621531
PMCID:
PMC4349585
DOI:
10.1021/jm501680m
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center